Iohexol Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-03

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of glomerular filtration rate using iohexol plasma clearance in critically ill patients with augmented renal creatinine clearance

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study

NCT02050269

Acute Circulatory Failure

COMPLETED PHASE3

Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure

NCT02961478

Acute Renal Failure

UNKNOWN PHASE3

Renal Function Assessment in Critically Ill Children

NCT05179564

Iohexol Pharmacokinetics Renal Function +3 more

COMPLETED NA

Acute Kidney Injury in Non-Critical Care Setting: Elaboration and Validation of an In-hospital Death Prognosis Score

NCT04242615

Intra-hospital Mortality Epidemiological Study

COMPLETED

Evaluation of the Performance of Glomerular Filtration Rate Measurement Using CT Urography in Patients With a GFR Below 60 mL/Min/1.73 m²

NCT07042698

Kidney Diseases Tomography X-Ray Computed

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Single center study in ICU patients with augmented renal clearance comparing glomerular filtration rate (GFR) as measured by iohexol plasma clearance to that measured by creatinine clearance. Primary objective is to compare the GFR estimates made by iohexol plasma clearance (as reference method) and creatinine clearance using Bland-Altman method.

Secondary objective are to compare GFR as measured by iohexol plasma clearance to that calculated with the most commonly used renal clearance estimating formulas (Cockcroft and Gault, MDRD and CKD-EPI ), evaluate clinical determinant of the observed differences and evaluate determinants of extracellular volume.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Augmented Renal Clearance Critically Ill

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Critically ill patients with augmented renal clearance

ICU patients with estimated renal clearance over 130ml/min/1.73m2

Group Type EXPERIMENTAL

Iohexol

Intervention Type DRUG

Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).

Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iohexol

Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).

Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Omnipaque

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ICU patient
* 24h Creatinine clearance \>130ml/min/1.73m2
* Urinary catheterization
* Affiliation to a social security scheme

Exclusion Criteria

* Pregnancy
* CT-scan with contrast media infusion the day of inclusion
* Documented allergy to contrast media
* Patient under guardianship / curatorship
* Patient benefiting from the "State Medical Assistance"

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No